Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/11816
Title: | Proteomics Investigations of Drug-Induced Hepatotoxicity in HepG2 Cells | Authors: | VAN SUMMEREN, Anke Renes, Johan Bouwman, Freek G. NOBEN, Jean-Paul VAN DELFT, Joost KLEINJANS, J. MARIMAN, Edwin |
Issue Date: | 2011 | Publisher: | OXFORD UNIV PRESS | Source: | TOXICOLOGICAL SCIENCES, 120(1). p. 109-122 | Abstract: | Unexpected hepatotoxicity is one of the major reasons of drugs failing in clinical trials. This emphasizes the need for new screening methods that address toxicological hazards early in the drug discovery process. Here, proteomics techniques were used to gain further insight into the mechanistic processes of the hepatotoxic compounds. Drug-induced hepatotoxicity is mainly divided in hepatic steatosis, cholestasis, or necrosis. For each class, a compound was selected, respectively amiodarone, cyclosporin A, and acetaminophen. The changes in protein expressions in HepG2, after exposure to these test compounds, were studied using quantitative two-dimensional differential gel electrophoresis. Identification of differentially expressed proteins was performed by Maldi-TOF/TOF MS and liquid chromatography-tandem mass spectrometry. In this study, 254 differentially expressed protein spots were detected in a two-dimensional proteome map from which 86 were identified, showing that the proteome of HepG2 cells is responsive to hepatotoxic compounds. cyclosporin A treatment was responsible for most differentially expressed proteins and could be discriminated in the hierarchical clustering analysis. The identified differential proteins show that cyclosporin A may induce endoplasmic reticulum (ER) stress and disturbs the ER-Golgi transport, with an altered vesicle-mediated transport and protein secretion as result. Moreover, the differential protein pattern seen after cyclosporin A treatment can be related to cholestatic mechanisms. Therefore, our findings indicate that the HepG2 in vitro cell system has distinctive characteristics enabling the assessment of cholestatic properties of novel compounds at an early stage of drug discovery. | Notes: | [Van Summeren, Anke; Renes, Johan; Bouwman, Freek G.; Mariman, Edwin C. M.] Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands. [Van Summeren, Anke; van Delft, Joost H. M.; Kleinjans, Jos C. S.] Maastricht Univ, Dept Risk Anal & Toxicol, NL-6200 MD Maastricht, Netherlands. [Noben, Jean-Paul] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium. [Noben, Jean-Paul] Transnat Univ Limburg, Sch Life Sci, Diepenbeek, Belgium. a.vansummeren@maastrichtuniversity.nl | Keywords: | HepG2; proteomics; hepatotoxicity; amiodarone; cyclosporin A; acetaminophen;HepG2; proteomics; hepatotoxicity; amiodarone; cyclosporin A; acetaminophen | Document URI: | http://hdl.handle.net/1942/11816 | ISSN: | 1096-6080 | e-ISSN: | 1096-0929 | DOI: | 10.1093/toxsci/kfq380 | ISI #: | 000287747800010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2012 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
noben 1.pdf | Published version | 607.77 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
54
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
66
checked on Oct 12, 2024
Page view(s)
178
checked on Sep 7, 2022
Download(s)
236
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.